Cost-effectiveness of partner pharmacotherapy in screening women for asymptomatic infection with Chlamydia trachomatis

Value in Health

Volumn 4, Issue 3, 2001, Pages 266-275

  Postma, Maarten J ^a   Welte, Robert ^b   Van Den Hoek, J Anneke R ^c   Van Doornum, Gerard J J ^d   Jager, Hans C ^b   Coutinho, Roel A ^c  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c MUNICIPAL HEALTH SERVICE   (Netherlands)

^d SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

Azithromycin; Chlamydia trachomatis; Cost effectiveness; LCR test; Screening

Indexed keywords

AZITHROMYCIN;

ARTICLE; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CONTACT EXAMINATION; COST EFFECTIVENESS ANALYSIS; FEMALE; GYNECOLOGIC INFECTION; HEALTH CARE COST; HUMAN; INFERTILITY; LIGASE CHAIN REACTION; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MODEL; PELVIC INFLAMMATORY DISEASE; PRIORITY JOURNAL; PRODUCTIVITY; SCREENING; TREATMENT OUTCOME; URINALYSIS;

EID: 0034940520     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4733.2001.43009.x     Document Type: Article

References (35)

1. Is screening for Chlamydia trachomatis infection cost-effective?
2. Health and cost-benefits of Chlamydia screening in young women
3. Chlamydia trachomatis in adolescents and adults
4. Is Europe ready for STD screening?
5. A cost-effectiveness analysis of screening and treatment for Chlamydia trachomatis infection in asymptomatic women
6. Epidemiologic and microbiologic correlates of Chlamydia trachomatis infection in sexual partnerships
7. Opportunistic screening for genital infections with Chlamydia trachomatis among the sexually active population of Amsterdam. I. Over 90% participation almost 5% prevalence
8. Pelvic Inflammatory Disease
9. Genital Chlamydial infections: Epidemiology and reproductive sequelae
10. Towards control of sexually transmitted Chlamydial infections
11. New opportunities for Chlamydia prevention; application of science to public health practice
12. Control of Chlamydia; a role for every clinician who sees sexually active patients
13. Screening for Chlamydia trachomatis in adolescent males: A cost-based decision analysis
14. An economic evaluation of screening for Chlamydia trachomatis in adolescent males
15. Performance and cost-effectiveness of selective screening criteria for Chlamydia trachomatis infection in women
16. Prevention of pelvic inflammatory disease by screening for cervical Chlamydial Infection
17. Incidence, prevalence and trends of acute pelvic inflammatory disease and its consequences in industrialized countries
18. Prospective study on perinatal transmission of Chlamydia trachomatis
19. Pelvic inflammatory disease and fertility; a cohort study of 1844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results
20. Should asymptomatic patients be tested for Chalmydia trachomatis in the general practice?
21. Pooling of urine specimens for PCR testing: A cost saving strategy for Chlamydia trachomatis control programs
22. Detection of Chlamydia trachomatis infection in urine samples from men and women by ligase chain reaction
23. Azithromycin; a pharmacoeconomic review of its use as a single-dose regimen in the treatment of uncomplicated urogenital Chlamydia trachomatis infections in women
24. Single-Dose azithromycin for Chlamydia in pregnant women
25. Partner referral by patients with gonorrhoeae and Chlamydial infection
26. Discounting and health benefits
27. Economic evaluation of influenza vaccination; assessment for The Netherlands
28. Universal HIV screening of pregnant women: Is it cost-effective in England?
29. Modeling prevention strategies for Gonorrhea and Chlamydia using stochastic network simulations